Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 916 to 930 of 2010 results for nice guidelines

  1. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

  2. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

  3. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  4. NPi-200 for pupillary light reflex in critical care patients (MIB235)

    NICE has developed a medtech innovation briefing (MIB) on NPi-200 for pupillary light reflex in critical care patients .

  5. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (HTG662)

    Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.

  6. Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure (HTG599)

    Evidence-based recommendations on percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure in adults. This involves putting a small electronic pressure sensor into the pulmonary artery to measure blood pressure.

  7. How we develop technology appraisal guidance

    A step-by-step summary about how we develop our technology appraisal guidance.

  8. Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis (HTG617)

    Evidence-based recommendations on percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. This involves inserting a tube called a stent into or across the cystic duct. The aim is to allow bile to flow through the tube, bypassing the blockage and preventing further obstruction.

  9. Laser lithotripsy for difficult-to-treat bile duct stones (HTG584)

    Evidence-based recommendations on laser lithotripsy for difficult-to-treat bile duct stones in adults. This involves breaking up the stones using laser light.

  10. Occipital nerve stimulation for intractable chronic migraine (HTG310)

    Evidence-based recommendations on occipital nerve stimulation for intractable chronic migraine. This involves using implanted electrodes to deliver electrical impulses to the occipital nerve to mask migraine pain.

  11. RespiraSense for continuously monitoring respiratory rate (MIB299)

    NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .

  12. Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

    Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.

  13. MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)

    NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes

  14. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

  15. Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG691)

    Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.